DENVER, April 07, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group™(CSE:MYCO)(OTC:MYCOF)(FSE: 0NFA)(“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has announced its four lead novel drug candidates as the Company prepares for its Pre-Investigational New Drug (IND) meetings with the FDA and Health Canada.
“Our first four novel drug candidates deliver on our long-term strategic road map for drug development with regular milestones that iteratively add value over time. By increasing the complexity of these compounds, we are increasing layers ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap . Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here .
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer .
For further details see:
Mydecine Announces API-Naming Structure of Four Lead Candidates and Prepares for Pre-IND